Overview
This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma.
The complete histological response will be assessed.
Eligibility
Inclusion Criteria:
- Patients with operable metastatic melanoma (stage III or IV of American Joint Committee on Cancer [AJCC] Stages CLassification) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due to disease progression or complete response or patient's refusal to be operated.
- Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed
Exclusion Criteria:
- Uveal melanoma